<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282421</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI014</org_study_id>
    <nct_id>NCT04282421</nct_id>
  </id_info>
  <brief_title>Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France</brief_title>
  <acronym>SYMFASCT</acronym>
  <official_title>Survival in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis in Five French Centers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would like to conduct a retrospective study in five centers in France in
      the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell
      transplantation for myelofibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The allogeneic stem cell transplantation is the only curative treatment for myelofibrosis.
      However, because of complications such as infection, graft-versus-host disease and
      conditioning toxicity, this procedure is associated with a high morbidity-mortality rate. The
      discovery of molecular and genetic markers permitted to improve therapeutic strategy and
      survival of patient in the last few years. In this study, the investigators want to make an
      overview of survival, incidence of relapse and incidence of acute and chronic graft versus
      host disease in allogeneic stem cell transplantation for myelofibrosis, in five centers in
      France, between 2007 and 2017.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2007</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>at 1 year</time_frame>
    <description>incidence of survival in the cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of relapse</measure>
    <time_frame>at 1 year</time_frame>
    <description>incidence of relapse in the cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of acute graft versus host disease</measure>
    <time_frame>at 3 months</time_frame>
    <description>incidence of acute graft versus host disease in the cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of chronic graft versus host disease</measure>
    <time_frame>at 1 year</time_frame>
    <description>incidence of chronic graft versus host disease in the cohort</description>
  </secondary_outcome>
  <enrollment type="Actual">58</enrollment>
  <condition>Myelofibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients receiving allogeneic hematopoietic stem cell transplantation for
        myelofibrosis in five centers in France (Nancy, Besançon, Strasbourg, Pitié Salpètrière and
        Lyon) between 2007 and 2017
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: adult patients receiving allogeneic hematopoietic stem cell
        transplantation for myelofibrosis in five centers in France (Nancy, Besancon, Strasbourg,
        Pitie Salpetriere and Lyon) between 2007 and 2017

        -

        Exclusion Criteria:

          -  age &lt; 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <reference>
    <citation>Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM, Shahswar R, Ayuk F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe HH, Ganser A, Stocking C, Fehse B, Thol F, Heuser M. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101. doi: 10.1016/j.bbmt.2017.03.034. Epub 2017 Apr 4.</citation>
    <PMID>28389256</PMID>
  </reference>
  <reference>
    <citation>Hussein K, Stucki-Koch A, Alchalby H, Triviai I, Kröger N, Kreipe H. Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis. Biol Blood Marrow Transplant. 2016 Apr;22(4):644-650. doi: 10.1016/j.bbmt.2015.12.006. Epub 2015 Dec 19.</citation>
    <PMID>26708839</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>survival</keyword>
  <keyword>graft versus host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

